Physiology / mechanism of action |
951 |
Toxicity |
952 |
Diagnosis |
953 |
Treatment |
954 |
Concluding remarks and future directions |
954 |
References |
954 |
Birgit Puschner | |
Introduction |
957 |
Background |
957 |
Hepatotoxic cyclopeptides |
958 |
Pharmacokinetics / toxicokinetics |
959 |
Mechanism of action |
959 |
Toxicity |
960 |
Treatment |
960 |
Hydrazines |
961 |
Pharmacokinetics / toxicokinetics |
962 |
Mechanism of action |
962 |
Toxicity |
962 |
Treatment |
962 |
Muscarinic agents |
963 |
Pharmacokinetics / toxicokinetics |
963 |
Mechanism of action |
963 |
Toxicity |
963 |
Treatment |
963 |
Isoxazoles |
963 |
Pharmacokinetics / toxicokinetics |
964 |
Mechanism of action |
964 |
Toxicity |
964 |
Treatment |
964 |
Psilocin and psilocybin |
965 |
Pharmacokinetics / toxicokinetics |
965 |
Mechanism of action |
965 |
Toxicity |
965 |
Treatment |
965 |
Gastrointestinal irritants |
966 |
Renal toxic mushrooms |
966 |
Ramaria flavo-brunnescens |
967 |
Concluding remarks and future | |
directions |
967 |
References |
967 |
Rhian B. Cope | |
Introduction |
973 |
Gossypol |
974 |
Introduction |
974 |
Dietary bioavailability and level of exposure |
975 |
Toxicokinetics |
976 |